Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis
- 1 August 2018
- journal article
- review article
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 55 (2) , 244-252
Abstract
No abstract availableKeywords
Funding Information
- Centers for Disease Control and Prevention
This publication has 37 references indexed in Scilit:
- Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant CandidatesTransplantation, 2017
- Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analysesBMC Infectious Diseases, 2017
- The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical ModellingPLOS Medicine, 2016
- Completion Rate and Side-Effect Profile of Three-Month Isoniazid and Rifapentine Treatment for Latent Tuberculosis Infection in an Urban County JailOpen Forum Infectious Diseases, 2016
- Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBIThe International Journal of Tuberculosis and Lung Disease, 2015
- Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis StudyClinical Infectious Diseases, 2015
- Weekly Rifapentine/Isoniazid or Daily Rifampin/Pyrazinamide for Latent Tuberculosis in Household ContactsAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- Controlled chemoprophylaxis trials in tuberculosis. A general review.1970